Recent News

• 09.05.2025 - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 09.04.2025 - Cantor Global Healthcare Conference
• 08.26.2025 - Vera Therapeutics to Participate at Upcoming Investor Conferences
• 08.08.2025 - Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2025 - Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
• 07.10.2025 - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.09.2025 - Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• 06.04.2025 - Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
• 06.03.2025 - Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans
• 06.02.2025 - Virtual Investor Event

Recent Filings

• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.05.2025 - 8-K Current report
• 08.05.2025 - 8-K Current report
• 08.05.2025 - EX-99.1 EX-99.1
• 08.05.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 06.25.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.11.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 06.03.2025 - 8-K Current report